A Phase 3 interventional study of Placebo and Vortioxetine in Generalized Anxiety Disorder, sponsored by Takeda. Completed at 66 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2013-12-18.
Sponsored by Takeda · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 265 studies in Generalized Anxiety Disorder with a site in United States — 38 open to participants now, 53 under way, 9 of them phase 3. Generalized Anxiety Disorder · United States.
Among the 265 studies in Generalized Anxiety Disorder with a site in United States, this one is the 8th largest by enrollment of the 234 interventional ones that give a count, is one of 20 that started in 2008, is one of 45 in phase 3, and was the 64th registered.
518 studies on the registry are indexed under Generalized Anxiety Disorder; 125 are open to participants now.
Browse Generalized Anxiety Disorder studies →38 of the 265 studies in Generalized Anxiety Disorder with a site in United States are open now. Recruiting first, the newest first:
Virginia Polytechnic Institute and State University · Sites in United States
Ages 18–65
Otsuka Pharmaceutical Development & Commercialization, Inc. · Sites in United States
Ages 18+
Intra-Cellular Therapies, Inc. · Sites in United States
Ages 18+
BTL Industries Ltd. · Sites in United States
Ages 22+
Intra-Cellular Therapies, Inc. · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 86 Generalized Anxiety Disorder studies recruiting now, 32 (37%) set no upper age limit and 52 (60%) stop at 75 or younger; 15 take children under 18; 16 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
265 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 32 · Phase 3 51 · Phase 4 28
First in 1991; this study’s year is marked. 20 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 781 is above the median of 83 across 440 interventional studies indexed under Generalized Anxiety Disorder.
Median enrollment 90 across the 234 interventional studies, 220 across the 28 observational. Of the 199 that completed or were terminated, 90 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
83 of 265 have an industry lead sponsor. The 10 most frequent:
Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.
Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.
Takeda has 5 studies filed under Generalized Anxiety Disorder — fewer than ten, so there is no comparison to draw.
20 of the studies in Generalized Anxiety Disorder with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07123467Phase 3Wayne State UniversityCannabidiol-Assisted Learning for Managing Generalized Anxiety Disorder | 2027-08-31 |
| NCT06846320AbbVieStudy to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder | 2026-11 |
| NCT06723158Boston UniversityOral Surgery Virtual Reality Glasses Study | 2026-12 |
| NCT04557891University of California, Los AngelesLow-Intensity Focused Ultrasound Pulsation (LIFUP) for the Treatment of Generalized Anxiety Disorder (GAD) | 2026-12 |
| NCT05467683Jasper A. SmitsCO2 Reactivity as a Biomarker of Non-Response to Exposure-Based Therapy | 2026-12-01 |
Add all 20 to your calendar (.ics) → With an account.
Among the 265 studies in Generalized Anxiety Disorder with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine the safety and efficacy of vortioxetine, once daily (QD), in adults with generalized anxiety disorder.
Participants in this study will be randomly assigned to receive either 2.5 mg, 5 mg or 10 mg of vortioxetine, once daily, 60 mg of duloxetine once daily, or a placebo once daily for eight weeks.
Participants will be seen weekly during the first 2 weeks of treatment, and then every 2 weeks up to the end of the 8-week treatment period. Participants who complete the 8-week treatment period will enter a 2-week discontinuation period in order to assess potential discontinuation symptoms. Total commitment time is up to 12 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Has 1 or more of the following:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Placebo-matching capsules, orally, once daily for up to 9 weeks.
Drug: Placebo
Vortioxetine 2.5 mg encapsulated tablets, orally, once daily, for 8 weeks, followed by placebo-matching capsules, orally, once daily, for 1 week.
Drug: Placebo · Drug: Vortioxetine
Vortioxetine 5 mg encapsulated tablets, orally, once daily, for 8 weeks, followed by placebo-matching capsules, orally, once daily, for 1 week.
Drug: Placebo · Drug: Vortioxetine
Vortioxetine 10 mg encapsulated tablets, orally, once daily, for 8 weeks, followed by placebo-matching capsules, orally, once daily, for 1 week.
Drug: Placebo · Drug: Vortioxetine
Duloxetine 60 mg capsules, orally, once daily, for 8 weeks, followed by duloxetine 30 mg capsules, orally, once daily, for 1 week.
Drug: Duloxetine
Placebo-matching capsules
Encapsulated vortioxetine immediate release tablets
Also known as: Lu AA21004, Brintellix®
Overencapsulated duloxetine capsules
Also known as: Cymbalta
Change From Baseline in the Hamilton Anxiety (HAM-A) Scale Total Score at Week 8
The HAM-A is an anxiety rating scale consisting of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behavior at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic and somatic (muscular) symptoms. Each symptom is rated from 0 (absent) to 4 (maximum severity). Total scores range from 0 to 56 where \<17 indicates mild severity, 18-24 mild to moderate severity and 25-30 moderate to severe. Total scores above 30 are rare, but indicate very severe anxiety. Least Squares (LS) means were from a mixed model for repeated measurements (MMRM) with week, Baseline score-by-week and treatment-by-week interaction as factors.
Time frame: Baseline to Week 8
Change From Baseline in Hospital Anxiety and Depression (HAD) - Anxiety Subscale at Week 8
The HAD-Anxiety subscale is completed by the participant and measures anxiety, including anxious mood, restlessness, anxious thoughts, and panic attacks. The subscale is made up of 7 items that are assessed on a scale from 0 (no anxiety) to 3 (severe feeling of anxiety). Participants are required to indicate the response which most accurately reflects the way they have felt over the last few days. Scores are summed and range from 0 to 21 (maximal severity). LS means were from a mixed model for repeated measurements (MMRM) with week, Baseline score-by-week and treatment-by-week interaction as factors.
Time frame: Baseline to Week 8
Mean Clinical Global Impression Scale-Global Improvement (CGI-I) at Week 8
The Clinical Global Impression - Global Improvement scale measures the participant's improvement (or worsening) as assessed by the investigator relative to Baseline on a 7-point scale: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; or 7, very much worse. LS means were from a mixed model for repeated measurements (MMRM) with week, Baseline score-by-week and treatment-by-week interaction as factors.
Time frame: Baseline to Week 8
Change From Baseline in Sheehan Disability Scale (SDS) at Week 8
The Sheehan Disability Scale assesses functional impairment in 3 domains: work/school, social life or leisure activities, and home life or family responsibilities. The participant rates the extent to which each aspect is impaired on a 10-point visual analog scale, from 0 (not at all) to 10 (extremely). The 3 scores are added together to calculate the total score, which ranges from 0 to 30, with higher scores indicating more impairment. LS means were from a mixed model for repeated measurements (MMRM) with week, Baseline score-by-week and treatment-by-week interaction as factors.
Time frame: Baseline to Week 8
Percentage of Responders in HAM-A Total Score at Week 8
Response was defined as participants with a ≥50% decrease from Baseline in the HAM-A total score. The HAM-A is an anxiety rating scale consisting of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behavior at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic and somatic (muscular) symptoms. Each symptom is rated from 0 (absent) to 4 (maximum severity). Total scores range from 0 (symptoms absent) to 56 (maximum severity).
Time frame: Week 8
Change From Baseline in the Hamilton Anxiety Scale (HAM-A) Total Score at Week 8 in Participants With Baseline HAM-A ≥25
The HAM-A is an anxiety rating scale consisting of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behavior at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic and somatic (muscular) symptoms. Each symptom is rated from 0 (absent) to 4 (maximum severity). Total scores range from 0 to 56 where \<17 indicates mild severity, 18-24 mild to moderate severity and 25-30 moderate to severe. Total scores above 30 are rare, but indicate very severe anxiety. LS means were from a mixed model for repeated measurements (MMRM) with week, Baseline score-by-week and treatment-by-week interaction as factors.
Time frame: Baseline to Week 8
Change From Baseline in Hamilton Anxiety Scale (HAM-A) Total Score at Other Weeks Assessed
The HAM-A is an anxiety rating scale consisting of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behavior at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic and somatic (muscular) symptoms. Each symptom is rated from 0 (absent) to 4 (maximum severity). Total scores range from 0 to 56 where \<17 indicates mild severity, 18-24 mild to moderate severity and 25-30 moderate to severe. Total scores above 30 are rare, but indicate very severe anxiety. LS means were from a mixed model for repeated measurements (MMRM) with week, Baseline score-by-week and treatment-by-week interaction as factors.
Time frame: Baseline to Weeks 1, 2, 4 and 6
Change From Baseline in Hospital Anxiety and Depression (HAD) - Anxiety Subscale at Other Weeks Assessed
The HAD-Anxiety subscale is completed by the participant and measures anxiety, including anxious mood, restlessness, anxious thoughts, and panic attacks. The subscale is made up of 7 items that are assessed on a scale from 0 (no anxiety) to 3 (severe feeling of anxiety). Participants are required to indicate the response which most accurately reflects the way they have felt over the last few days. Scores are summed and range from 0 to 21 (maximal severity). LS means were from a mixed model for repeated measurements (MMRM) with week, Baseline score-by-week and treatment-by-week interaction as factors.
Time frame: Baseline to Weeks 1 and 4
Mean Clinical Global Impression Scale-Global Improvement (CGI-I) at Other Weeks Assessed
The Clinical Global Impression - Global Improvement scale measures the participant's improvement (or worsening) as assessed by the clinician relative to Baseline on a 7-point scale: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; or 7, very much worse. LS means were from a mixed model for repeated measurements (MMRM) with week, Baseline score-by-week and treatment-by-week interaction as factors.
Time frame: Baseline to Weeks 1, 2, 4 and 6
Change From Baseline in Sheehan Disability Scale (SDS) at Other Weeks Assessed
The Sheehan Disability Scale assesses functional impairment in 3 domains: work/school, social life or leisure activities, and home life or family responsibilities. The participant rates the extent to which each aspect is impaired on a 10-point visual analog scale, from 0 (not at all) to 10 (extremely). The 3 scores are added together to calculate the total score, which ranges from 0 to 30, with higher scores indicating more impairment. LS means were from a mixed model for repeated measurements (MMRM) with week, Baseline score-by-week and treatment-by-week interaction as factors.
Time frame: Baseline to Weeks 1, 2 and 4
Percentage of Responders in HAM-A Total Score at Other Weeks Assessed
Response was defined as participants with a ≥50% decrease from Baseline in the HAM-A total score. The HAM-A is an anxiety rating scale consisting of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behavior at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic and somatic (muscular) symptoms. Each symptom is rated from 0 (absent) to 4 (maximum severity). Total scores range from 0 (symptoms absent) to 56 (maximum severity).
Time frame: Baseline and Weeks 1, 2, 4 and 6
Change From Baseline in the Hamilton Anxiety Scale (HAM-A) Total Score at Other Weeks Assessed in Participants With Baseline HAM-A ≥25
The HAM-A is an anxiety rating scale consisting of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behavior at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic and somatic (muscular) symptoms. Each symptom is rated from 0 (absent) to 4 (maximum severity). Total scores range from 0 to 56 where \<17 indicates mild severity, 18-24 mild to moderate severity and 25-30 moderate to severe. Total scores above 30 are rare, but indicate very severe anxiety. LS means were from a mixed model for repeated measurements (MMRM) with week, Baseline score-by-week and treatment-by-week interaction as factors.
Time frame: Baseline to weeks 1, 2, 4 and 6
Percentage of Participants in HAM-A Remission at Each Week Assessed
Remission is defined as a Hamilton Anxiety Scale (HAM-A) total score ≤ 7. The HAM-A is an anxiety rating scale consisting of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behavior at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic and somatic (muscular) symptoms. Each symptom is rated from 0 (absent) to 4 (maximum severity). Total scores range from 0 (symptoms absent) to 56 (maximum severity).
Time frame: Weeks 1, 2, 4, 6 and 8
Change From Baseline in Clinical Global Impression Scale-Severity of Illness (CGI-S)
The Clinical Global Impression - Severity scale (CGI-S) is a 7-point scale that requires the clinician to rate the severity of the patient's illness at the time of assessment, relative to the clinician's past experience with patients who have the same diagnosis. Considering total clinical experience, a patient is assessed on severity of mental illness on the following scale: 1, normal, not at all ill; 2, borderline mentally ill; 3, mildly ill; 4, moderately ill; 5, markedly ill; 6, severely ill; or 7, extremely ill. LS means were from a mixed model for repeated measurements (MMRM) with week, Baseline score-by-week and treatment-by-week interaction as factors.
Time frame: Baseline to Weeks 1, 2, 4, 6 and 8
Change From Baseline in Hospital Anxiety and Depression (HAD) - Depression Subscale at All Weeks Assessed
The HAD-Depression subscale is completed by the participant and measures depression, focusing on the state of lost interest and diminished pleasure response. The subscale is made up of 7 items that are assessed on a scale from 0 (no depression) to 3 (severe feeling of depression). Participants are required to indicate the response which most accurately reflects the way they have felt over the last few days. The item scores are summed and the total subscore ranges from 0 to 21 (maximal severity). LS means were from a mixed model for repeated measurements (MMRM) model with week, Baseline score-by-week and treatment-by-week interaction as factors.
Time frame: Baseline to Weeks 1, 4 and 8
Health Care Resource Utilization Assessed by the Health Economic Assessment Questionnaire
Healthcare resource utilization was assessed by the Health Economic Assessment (HEA) questionnaire, which monitors the participants absenteeism from work, as well as resource use such as visits to a general practitioner, outpatient and inpatient services, hospitalization, medications, and other relevant services over the past 8 weeks.
Time frame: Baseline and Week 8
Participants took part in the study at 71 investigative sites in the United States from 20 June 2008 to 27 February 2009.
| Milestone | Placebo | Vortioxetine 2.5 mg | Vortioxetine 5 mg | Vortioxetine 10 mg | Duloxetine 60 mg |
|---|---|---|---|---|---|
| Started | 157 | 156 | 156 | 156 | 156 |
| Completed | 121 | 120 | 117 | 111 | 106 |
| Not completed | 36 | 36 | 39 | 45 | 50 |
| Withdrew: Adverse event | 4 | 8 | 11 | 11 | 23 |
| Withdrew: Lack of efficacy | 4 | 4 | 2 | 1 | 1 |
| Withdrew: Non-compliance with study drug | 6 | 1 | 6 | 3 | 3 |
| Withdrew: Protocol deviations | 3 | 5 | 3 | 7 | 5 |
| Withdrew: Withdrawal of consent | 7 | 9 | 3 | 6 | 3 |
| Withdrew: Lost to follow-up | 11 | 8 | 13 | 15 | 13 |
| Withdrew: Other | 1 | 1 | 1 | 2 | 2 |
The HAM-A is an anxiety rating scale consisting of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behavior at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic and somatic (muscular) symptoms. Each symptom is rated from 0 (absent) to 4 (maximum severity). Total scores range from 0 to 56 where \<17 indicates mild severity, 18-24 mild to moderate severity and 25-30 moderate to severe. Total scores above 30 are rare, but indicate very severe anxiety. Least Squares (LS) means were from a mixed model for repeated measurements (MMRM) with week, Baseline score-by-week and treatment-by-week interaction as factors.
| scores on a scale | Placebo | Vortioxetine 2.5 mg | Vortioxetine 5 mg | Vortioxetine 10 mg | Duloxetine 60 mg |
|---|---|---|---|---|---|
| Change From Baseline in the Hamilton Anxiety (HAM-A) Scale Total Score at Week 8 | -11.27 ± 0.595 | -12.23 ± 0.600 | -11.57 ± 0.606 | -11.66 ± 0.606 | -13.87 ± 0.635 |
The HAD-Anxiety subscale is completed by the participant and measures anxiety, including anxious mood, restlessness, anxious thoughts, and panic attacks. The subscale is made up of 7 items that are assessed on a scale from 0 (no anxiety) to 3 (severe feeling of anxiety). Participants are required to indicate the response which most accurately reflects the way they have felt over the last few days. Scores are summed and range from 0 to 21 (maximal severity). LS means were from a mixed model for repeated measurements (MMRM) with week, Baseline score-by-week and treatment-by-week interaction as factors.
| scores on a scale | Placebo | Vortioxetine 2.5 mg | Vortioxetine 5 mg | Vortioxetine 10 mg | Duloxetine 60 mg |
|---|---|---|---|---|---|
| Change From Baseline in Hospital Anxiety and Depression (HAD) - Anxiety Subscale at Week 8 | -4.00 ± 0.361 | -3.89 ± 0.364 | -4.24 ± 0.366 | -5.09 ± 0.372 | -5.54 ± 0.385 |
The Clinical Global Impression - Global Improvement scale measures the participant's improvement (or worsening) as assessed by the investigator relative to Baseline on a 7-point scale: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; or 7, very much worse. LS means were from a mixed model for repeated measurements (MMRM) with week, Baseline score-by-week and treatment-by-week interaction as factors.
| scores on a scale | Placebo | Vortioxetine 2.5 mg | Vortioxetine 5 mg | Vortioxetine 10 mg | Duloxetine 60 mg |
|---|---|---|---|---|---|
| Mean Clinical Global Impression Scale-Global Improvement (CGI-I) at Week 8 | 2.47 ± 0.091 | 2.36 ± 0.092 | 2.38 ± 0.093 | 2.38 ± 0.093 | 2.03 ± 0.098 |
The Sheehan Disability Scale assesses functional impairment in 3 domains: work/school, social life or leisure activities, and home life or family responsibilities. The participant rates the extent to which each aspect is impaired on a 10-point visual analog scale, from 0 (not at all) to 10 (extremely). The 3 scores are added together to calculate the total score, which ranges from 0 to 30, with higher scores indicating more impairment. LS means were from a mixed model for repeated measurements (MMRM) with week, Baseline score-by-week and treatment-by-week interaction as factors.
| scores on a scale | Placebo | Vortioxetine 2.5 mg | Vortioxetine 5 mg | Vortioxetine 10 mg | Duloxetine 60 mg |
|---|---|---|---|---|---|
| Change From Baseline in Sheehan Disability Scale (SDS) at Week 8 | -6.35 ± 0.631 | -6.15 ± 0.647 | -6.68 ± 0.642 | -7.95 ± 0.623 | -8.81 ± 0.675 |
Response was defined as participants with a ≥50% decrease from Baseline in the HAM-A total score. The HAM-A is an anxiety rating scale consisting of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behavior at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic and somatic (muscular) symptoms. Each symptom is rated from 0 (absent) to 4 (maximum severity). Total scores range from 0 (symptoms absent) to 56 (maximum severity).
| percentage of participants | Placebo | Vortioxetine 2.5 mg | Vortioxetine 5 mg | Vortioxetine 10 mg | Duloxetine 60 mg |
|---|---|---|---|---|---|
| Percentage of Responders in HAM-A Total Score at Week 8 | 42.2 | 44.8 | 42.6 | 44.8 | 51.0 |
The HAM-A is an anxiety rating scale consisting of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behavior at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic and somatic (muscular) symptoms. Each symptom is rated from 0 (absent) to 4 (maximum severity). Total scores range from 0 to 56 where \<17 indicates mild severity, 18-24 mild to moderate severity and 25-30 moderate to severe. Total scores above 30 are rare, but indicate very severe anxiety. LS means were from a mixed model for repeated measurements (MMRM) with week, Baseline score-by-week and treatment-by-week interaction as factors.
| scores on a scale | Placebo | Vortioxetine 2.5 mg | Vortioxetine 5 mg | Vortioxetine 10 mg | Duloxetine 60 mg |
|---|---|---|---|---|---|
| Change From Baseline in the Hamilton Anxiety Scale (HAM-A) Total Score at Week 8 in Participants With Baseline HAM-A ≥25 | -11.61 ± 1.008 | -14.12 ± 0.945 | -13.87 ± 0.955 | -13.22 ± 0.999 | -16.15 ± 1.039 |
The HAM-A is an anxiety rating scale consisting of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behavior at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic and somatic (muscular) symptoms. Each symptom is rated from 0 (absent) to 4 (maximum severity). Total scores range from 0 to 56 where \<17 indicates mild severity, 18-24 mild to moderate severity and 25-30 moderate to severe. Total scores above 30 are rare, but indicate very severe anxiety. LS means were from a mixed model for repeated measurements (MMRM) with week, Baseline score-by-week and treatment-by-week interaction as factors.
| scores on a scale | Placebo | Vortioxetine 2.5 mg | Vortioxetine 5 mg | Vortioxetine 10 mg | Duloxetine 60 mg |
|---|---|---|---|---|---|
| Week 1 (n= 151, 149, 142, 149, 143) | -4.70 ± 0.423 | -4.56 ± 0.421 | -4.90 ± 0.430 | -5.04 ± 0.419 | -5.48 ± 0.435 |
| Week 2 (n=147, 145, 143, 147, 130) | -7.30 ± 0.472 | -7.28 ± 0.471 | -8.22 ± 0.476 | -7.63 ± 0.468 | -9.29 ± 0.494 |
| Week 4 (n= 139, 135, 132, 133, 116) | -8.66 ± 0.518 | -9.77 ± 0.520 | -9.84 ± 0.525 | -9.73 ± 0.519 | -11.13 ± 0.553 |
| Week 6 (n= 127, 123, 122, 120, 112) | -10.28 ± 0.547 | -10.82 ± 0.553 | -11.26 ± 0.556 | -11.05 ± 0.552 | -12.66 ± 0.583 |
The HAD-Anxiety subscale is completed by the participant and measures anxiety, including anxious mood, restlessness, anxious thoughts, and panic attacks. The subscale is made up of 7 items that are assessed on a scale from 0 (no anxiety) to 3 (severe feeling of anxiety). Participants are required to indicate the response which most accurately reflects the way they have felt over the last few days. Scores are summed and range from 0 to 21 (maximal severity). LS means were from a mixed model for repeated measurements (MMRM) with week, Baseline score-by-week and treatment-by-week interaction as factors.
| scores on a scale | Placebo | Vortioxetine 2.5 mg | Vortioxetine 5 mg | Vortioxetine 10 mg | Duloxetine 60 mg |
|---|---|---|---|---|---|
| Week 1 (n=150, 149, 141, 149, 141) | -1.81 ± 0.273 | -1.85 ± 0.274 | -1.89 ± 0.280 | -2.22 ± 0.272 | -2.91 ± 0.285 |
| Week 4 (n=141, 142, 139, 141, 126) | -3.24 ± 0.310 | -3.34 ± 0.310 | -3.60 ± 0.313 | -4.01 ± 0.310 | -5.11 ± 0.328 |
The Clinical Global Impression - Global Improvement scale measures the participant's improvement (or worsening) as assessed by the clinician relative to Baseline on a 7-point scale: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; or 7, very much worse. LS means were from a mixed model for repeated measurements (MMRM) with week, Baseline score-by-week and treatment-by-week interaction as factors.
| scores on a scale | Placebo | Vortioxetine 2.5 mg | Vortioxetine 5 mg | Vortioxetine 10 mg | Duloxetine 60 mg |
|---|---|---|---|---|---|
| Week 1 (n=151, 148, 141, 149, 141) | 3.44 ± 0.067 | 3.46 ± 0.068 | 3.41 ± 0.069 | 3.40 ± 0.067 | 3.36 ± 0.070 |
| Week 2 (n=147, 145, 142, 147, 129) | 3.03 ± 0.072 | 3.08 ± 0.072 | 2.90 ± 0.073 | 2.96 ± 0.072 | 2.76 ± 0.077 |
| Week 4 (n=140, 135, 132, 134, 116) | 2.81 ± 0.079 | 2.67 ± 0.080 | 2.67 ± 0.081 | 2.68 ± 0.080 | 2.44 ± 0.085 |
| Week 6 (n=127, 123, 121, 120, 112) | 2.61 ± 0.082 | 2.53 ± 0.083 | 2.43 ± 0.084 | 2.41 ± 0.083 | 2.25 ± 0.088 |
The Sheehan Disability Scale assesses functional impairment in 3 domains: work/school, social life or leisure activities, and home life or family responsibilities. The participant rates the extent to which each aspect is impaired on a 10-point visual analog scale, from 0 (not at all) to 10 (extremely). The 3 scores are added together to calculate the total score, which ranges from 0 to 30, with higher scores indicating more impairment. LS means were from a mixed model for repeated measurements (MMRM) with week, Baseline score-by-week and treatment-by-week interaction as factors.
| scores on a scale | Placebo | Vortioxetine 2.5 mg | Vortioxetine 5 mg | Vortioxetine 10 mg | Duloxetine 60 mg |
|---|---|---|---|---|---|
| Week 1 (n=116, 111, 109, 125, 112) | -3.22 ± 0.506 | -2.74 ± 0.521 | -3.28 ± 0.521 | -4.11 ± 0.483 | -4.74 ± 0.521 |
| Week 2 (n=116, 114, 116, 123, 103) | -4.53 ± 0.536 | -4.18 ± 0.547 | -5.02 ± 0.542 | -5.46 ± 0.514 | -7.09 ± 0.563 |
| Week 4 (n=108, 106, 106, 115, 91) | -4.55 ± 0.590 | -4.98 ± 0.604 | -5.92 ± 0.600 | -6.47 ± 0.568 | -7.95 ± 0.632 |
Response was defined as participants with a ≥50% decrease from Baseline in the HAM-A total score. The HAM-A is an anxiety rating scale consisting of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behavior at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic and somatic (muscular) symptoms. Each symptom is rated from 0 (absent) to 4 (maximum severity). Total scores range from 0 (symptoms absent) to 56 (maximum severity).
| percentage of participants | Placebo | Vortioxetine 2.5 mg | Vortioxetine 5 mg | Vortioxetine 10 mg | Duloxetine 60 mg |
|---|---|---|---|---|---|
| Week 1 (n=151, 149, 142, 149, 143) | 11.3 | 6.7 | 8.5 | 10.1 | 16.8 |
| Week 2 (n=154, 154, 147, 154, 149) | 20.8 | 20.1 | 21.1 | 21.4 | 28.9 |
| Week 4 (n=154, 154, 148, 154, 149) | 26.0 | 30.5 | 32.4 | 35.1 | 42.3 |
| Week 6 (n=154, 154, 148, 154, 149) | 36.4 | 37.7 | 40.5 | 40.9 | 47.7 |
The HAM-A is an anxiety rating scale consisting of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behavior at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic and somatic (muscular) symptoms. Each symptom is rated from 0 (absent) to 4 (maximum severity). Total scores range from 0 to 56 where \<17 indicates mild severity, 18-24 mild to moderate severity and 25-30 moderate to severe. Total scores above 30 are rare, but indicate very severe anxiety. LS means were from a mixed model for repeated measurements (MMRM) with week, Baseline score-by-week and treatment-by-week interaction as factors.
| scores on a scale | Placebo | Vortioxetine 2.5 mg | Vortioxetine 5 mg | Vortioxetine 10 mg | Duloxetine 60 mg |
|---|---|---|---|---|---|
| Week 1 (n=63, 76, 70, 70, 66) | -5.32 ± 0.787 | -6.07 ± 0.719 | -5.96 ± 0.749 | -5.94 ± 0.740 | -6.78 ± 0.770 |
| Week 2 (n=62, 73, 70, 68, 62) | -7.55 ± 0.856 | -8.82 ± 0.785 | -10.18 ± 0.810 | -8.51 ± 0.808 | -10.40 ± 0.844 |
| Week 4 (n=60, 68, 67, 63, 54) | -8.61 ± 0.901 | -11.61 ± 0.837 | -12.87 ± 0.854 | -10.98 ± 0.862 | -12.56 ± 0.914 |
| Week 6 (n=58, 63, 62, 54, 51) | -10.72 ± 0.937 | -12.86 ± 0.880 | -14.11 ± 0.895 | -12.75 ± 0.918 | -14.35 ± 0.961 |
Remission is defined as a Hamilton Anxiety Scale (HAM-A) total score ≤ 7. The HAM-A is an anxiety rating scale consisting of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behavior at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic and somatic (muscular) symptoms. Each symptom is rated from 0 (absent) to 4 (maximum severity). Total scores range from 0 (symptoms absent) to 56 (maximum severity).
| percentage of participants | Placebo | Vortioxetine 2.5 mg | Vortioxetine 5 mg | Vortioxetine 10 mg | Duloxetine 60 mg |
|---|---|---|---|---|---|
| Week 1 (n=151, 149, 142, 149, 143) | 4.0 | 2.0 | 0.7 | 2.0 | 4.9 |
| Week 2 (n=154, 154, 147, 154, 149) | 6.5 | 8.4 | 7.5 | 3.9 | 12.1 |
| Week 4 (n=154, 154, 148, 154, 149) | 10.4 | 13.6 | 11.5 | 13.0 | 17.4 |
| Week 6 (n=154, 154, 148, 154, 149) | 16.2 | 14.9 | 14.9 | 16.9 | 20.8 |
| Week 8 (n=154, 154, 148, 154, 149) | 22.1 | 20.1 | 19.6 | 20.1 | 28.2 |
The Clinical Global Impression - Severity scale (CGI-S) is a 7-point scale that requires the clinician to rate the severity of the patient's illness at the time of assessment, relative to the clinician's past experience with patients who have the same diagnosis. Considering total clinical experience, a patient is assessed on severity of mental illness on the following scale: 1, normal, not at all ill; 2, borderline mentally ill; 3, mildly ill; 4, moderately ill; 5, markedly ill; 6, severely ill; or 7, extremely ill. LS means were from a mixed model for repeated measurements (MMRM) with week, Baseline score-by-week and treatment-by-week interaction as factors.
| scores on a scale | Placebo | Vortioxetine 2.5 mg | Vortioxetine 5 mg | Vortioxetine 10 mg | Duloxetine 60 mg |
|---|---|---|---|---|---|
| Week 1 (n=151, 148, 141, 149, 142) | -0.42 ± 0.055 | -0.37 ± 0.055 | -0.39 ± 0.056 | -0.42 ± 0.054 | -0.54 ± 0.057 |
| Week 2 (n=147, 145, 142, 147, 130) | -0.71 ± 0.066 | -0.74 ± 0.066 | -0.80 ± 0.067 | -0.75 ± 0.065 | -0.97 ± 0.069 |
| Week 4 (n=140, 135, 132, 134, 115) | -0.95 ± 0.076 | -1.12 ± 0.077 | -1.02 ± 0.077 | -1.11 ± 0.076 | -1.28 ± 0.082 |
| Week 6 (n=127, 123, 121, 120, 112) | -1.22 ± 0.083 | -1.32 ± 0.084 | -1.31 ± 0.084 | -1.35 ± 0.084 | -1.55 ± 0.088 |
| Week 8 (n=120, 118, 114, 111, 106) | -1.42 ± 0.095 | -1.50 ± 0.096 | -1.38 ± 0.097 | -1.44 ± 0.097 | -1.77 ± 0.101 |
The HAD-Depression subscale is completed by the participant and measures depression, focusing on the state of lost interest and diminished pleasure response. The subscale is made up of 7 items that are assessed on a scale from 0 (no depression) to 3 (severe feeling of depression). Participants are required to indicate the response which most accurately reflects the way they have felt over the last few days. The item scores are summed and the total subscore ranges from 0 to 21 (maximal severity). LS means were from a mixed model for repeated measurements (MMRM) model with week, Baseline score-by-week and treatment-by-week interaction as factors.
| scores on a scale | Placebo | Vortioxetine 2.5 mg | Vortioxetine 5 mg | Vortioxetine 10 mg | Duloxetine 60 mg |
|---|---|---|---|---|---|
| Week 1 (n=150, 149, 141, 149, 141) | -0.81 ± 0.226 | -0.83 ± 0.226 | -0.88 ± 0.231 | -1.25 ± 0.225 | -1.19 ± 0.235 |
| Week 4 (n=141, 142, 139, 141, 126) | -1.32 ± 0.268 | -1.83 ± 0.268 | -1.70 ± 0.271 | -1.61 ± 0.268 | -2.62 ± 0.283 |
| Week 8 (n=123, 120, 119, 111, 108) | -2.21 ± 0.300 | -1.82 ± 0.303 | -1.96 ± 0.305 | -1.94 ± 0.310 | -2.77 ± 0.320 |
Healthcare resource utilization was assessed by the Health Economic Assessment (HEA) questionnaire, which monitors the participants absenteeism from work, as well as resource use such as visits to a general practitioner, outpatient and inpatient services, hospitalization, medications, and other relevant services over the past 8 weeks.
| participants | Placebo | Vortioxetine 2.5 mg | Vortioxetine 5 mg | Vortioxetine 10 mg | Duloxetine 60 mg |
|---|---|---|---|---|---|
| Baseline: Any resource use | 34 | 36 | 26 | 43 | 38 |
| Baseline: Any hospitalization-related services | 0 | 3 | 1 | 0 | 2 |
| Baseline: Hospitalization related to anxiety | 0 | 2 | 1 | 0 | 0 |
| Baseline: Any sick leave | 14 | 16 | 13 | 15 | 12 |
| Baseline: Sick leave related to anxiety | 5 | 10 | 9 | 9 | 7 |
| Week 8: Any resource use | 26 | 24 | 29 | 23 | 22 |
| Week 8: Any hospitalization-related service | 0 | 0 | 0 | 1 | 3 |
| Week 8: Hospitalization related to anxiety | 0 | 0 | 0 | 0 | 1 |
| Week 8: Any sick leave | 13 | 6 | 7 | 7 | 11 |
| Week 8: Sick leave related to anxiety | 2 | 2 | 3 | 1 | 4 |
Collected over From the first dose of double-blind study medication through 30 days after permanent discontinuation of double-blind study medication.. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 0/155 (0%) | 85/155 (54.8%) |
| Vortioxetine 2.5 mg | — | 1/156 (0.6%) | 100/156 (64.1%) |
| Vortioxetine 5 mg | — | 0/155 (0%) | 104/155 (67.1%) |
| Vortioxetine 10 mg | — | 1/156 (0.6%) | 111/156 (71.2%) |
| Duloxetine 60 mg | — | 3/154 (1.9%) | 116/154 (75.3%) |
| Event | Placebo | Vortioxetine 2.5 mg | Vortioxetine 5 mg | Vortioxetine 10 mg | Duloxetine 60 mg |
|---|---|---|---|---|---|
| Angina pectorisCardiac disorders | 0/155 | 0/156 | 0/155 | 0/156 | 1/154 |
| SomnolenceNervous system disorders | 0/155 | 0/156 | 0/155 | 0/156 | 1/154 |
| Sexual abuseSocial circumstances | 0/155 | 0/156 | 0/155 | 0/156 | 1/154 |
| Abdominal herniaGastrointestinal disorders | 0/155 | 0/156 | 0/155 | 1/156 | 0/154 |
| Benign prostatic hyperplasiaReproductive system and breast disorders | 0/155 | 1/156 | 0/155 | 0/156 | 0/154 |
| Event | Placebo | Vortioxetine 2.5 mg | Vortioxetine 5 mg | Vortioxetine 10 mg | Duloxetine 60 mg |
|---|---|---|---|---|---|
| NauseaGastrointestinal disorders | 27/155 | 26/156 | 45/155 | 53/156 | 57/154 |
| HeadacheNervous system disorders | 20/155 | 18/156 | 20/155 | 25/156 | 26/154 |
| Dry mouthGastrointestinal disorders | 10/155 | 14/156 | 17/155 | 21/156 | 25/154 |
| DiarrhoeaGastrointestinal disorders | 9/155 | 9/156 | 11/155 | 20/156 | 6/154 |
| SomnolenceNervous system disorders | 6/155 | 7/156 | 13/155 | 8/156 | 18/154 |
| DizzinessNervous system disorders | 5/155 | 13/156 | 9/155 | 14/156 | 17/154 |
| FatigueGeneral disorders | 3/155 | 6/156 | 8/155 | 9/156 | 15/154 |
| NasopharyngitisInfections and infestations | 7/155 | 14/156 | 7/155 | 12/156 | 3/154 |
| ConstipationGastrointestinal disorders | 6/155 | 10/156 | 4/155 | 12/156 | 8/154 |
| Upper respiratory tract infectionInfections and infestations | 9/155 | 12/156 | 11/155 | 12/156 | 8/154 |
| Age Continuous(years) | Placebo | Vortioxetine 2.5 mg | Vortioxetine 5 mg | Vortioxetine 10 mg | Duloxetine 60 mg | Total |
|---|---|---|---|---|---|---|
| Mean | 36.8 ± 12.12 | 39.2 ± 11.90 | 37.7 ± 11.96 | 39.8 ± 12.33 | 39.5 ± 12.28 | 38.6 ± 12.14 |
| Age, Customized(participants) | Placebo | Vortioxetine 2.5 mg | Vortioxetine 5 mg | Vortioxetine 10 mg | Duloxetine 60 mg | Total |
|---|---|---|---|---|---|---|
| ≤55 years | 143 | 140 | 147 | 137 | 137 | 704 |
| >55 years | 14 | 16 | 9 | 19 | 19 | 77 |
| Sex: Female, Male(Participants) | Placebo | Vortioxetine 2.5 mg | Vortioxetine 5 mg | Vortioxetine 10 mg | Duloxetine 60 mg | Total |
|---|---|---|---|---|---|---|
| Female | 102 | 109 | 100 | 105 | 113 | 529 |
| Male | 55 | 47 | 56 | 51 | 43 | 252 |
| Race/Ethnicity, Customized(participants) | Placebo | Vortioxetine 2.5 mg | Vortioxetine 5 mg | Vortioxetine 10 mg | Duloxetine 60 mg | Total |
|---|---|---|---|---|---|---|
| Caucasian (White, including Hispanic) | 118 | 121 | 124 | 120 | 121 | 604 |
| Black | 35 | 31 | 26 | 33 | 31 | 156 |
| Asian | 4 | 0 | 6 | 0 | 4 | 14 |
| American Indian or Alaska Native | 0 | 1 | 0 | 2 | 0 | 3 |
| Native Hawaiian/ Other Pacific Islander | 0 | 1 | 0 | 1 | 0 | 2 |
| Region of Enrollment(participants) | Placebo | Vortioxetine 2.5 mg | Vortioxetine 5 mg | Vortioxetine 10 mg | Duloxetine 60 mg | Total |
|---|---|---|---|---|---|---|
| United States | 157 | 156 | 156 | 156 | 156 | 781 |
| Weight(kg) | Placebo | Vortioxetine 2.5 mg | Vortioxetine 5 mg | Vortioxetine 10 mg | Duloxetine 60 mg | Total |
|---|---|---|---|---|---|---|
| Mean | 84.40 ± 25.426 | 79.47 ± 19.893 | 80.98 ± 20.312 | 80.17 ± 21.420 | 79.51 ± 20.090 | 80.91 ± 21.558 |
| Height(cm) | Placebo | Vortioxetine 2.5 mg | Vortioxetine 5 mg | Vortioxetine 10 mg | Duloxetine 60 mg | Total |
|---|---|---|---|---|---|---|
| Mean | 168.74 ± 9.605 | 167.87 ± 9.139 | 169.25 ± 9.282 | 167.61 ± 8.378 | 167.94 ± 9.300 | 168.28 ± 9.147 |
| Body Mass Index (BMI)(kg/m^2) | Placebo | Vortioxetine 2.5 mg | Vortioxetine 5 mg | Vortioxetine 10 mg | Duloxetine 60 mg | Total |
|---|---|---|---|---|---|---|
| Mean | 29.54 ± 8.478 | 28.19 ± 6.651 | 28.24 ± 6.589 | 28.49 ± 7.058 | 28.10 ± 6.325 | 28.51 ± 7.064 |
7 further baseline measures are reported on the registry.
The record gives a start of Jun 2008, a primary completion of Feb 2009 and a completion of Feb 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2013, 4 years 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Vortioxetine
Generalized Anxiety Disorder →